Ovarian Function Suppression for Breast Cancer Clinical Trial Recruiting Soon

Strategic Insights -

Researchers at the University of Michigan Rogel Cancer Center are nearing the recruitment phase for a Phase 2 clinical trial examining the effects of ovarian function suppression for breast cancer patients. The trial, led by principal investigator Norah L. Henry, aims to compare the efficacy of leuprolide at different doses to goserelin in suppressing estrogen production in pre- or peri-menopausal women with breast cancer.

Key Takeaways:

  • The trial, Phase 2, is designed to compare leuprolide at two different doses to goserelin in suppressing estrogen production in pre- or peri-menopausal women with breast cancer.
  • The primary objective of the study is to determine if lower dose leuprolide, higher dose leuprolide, and goserelin are as safe, tolerable, and effective in suppressing ovarian function in breast cancer patients.
  • The trial will include 75 participants from the USA and is being conducted to evaluate the potential benefits of ovarian function suppression in breast cancer treatment.
  • This trial is one of several ongoing studies aimed at exploring novel approaches to breast cancer treatment.

Statistics:

  • 75 participants will be recruited for the trial from the USA.
  • Two different doses of leuprolide and one dose of goserelin will be compared in terms of their ability to suppress ovarian function in breast cancer patients.
  • The trial aims to assess the efficacy and safety of leuprolide and goserelin in reducing estrogen production in pre- or peri-menopausal women with breast cancer.

Sources:

  • ClinicalTrials.gov
  • https://clinicaltrials.gov/study/NCT07158021